Search Prime Grants

R01AG070919

Project Grant

Overview

Grant Description
Regulation of Cholesterol by γ-Secretase and ApoE: Implications for AD Pathogenesis and Synaptic Function - Alzheimer's disease (AD) is the most common neurodegenerative disorder in the United States that affects more than 5 million Americans. Synapses are the earliest affected component of the brain during AD pathogenesis, suggesting that the cognitive decline and neuronal loss in AD initiates with synaptic dysfunction.

Despite much effort, however, no definitive understanding of AD pathogenesis is available, and no therapies that alleviate or even stop progression of AD are known. Genetic studies identified rare mutations in presenilin and in APP genes that cause early-onset familial AD (FAD), and described common variants in several genes, chiefly the ApoE and TREM2 genes, that predispose to sporadic AD, providing potential clues to AD pathogenesis.

Presenilin mutations impair the activity of γ-secretase, an intramembranous protease that cleaves a large number of membrane proteins, including APP. Presenilin and APP mutations associated with FAD both enhance production of Aβ, a cleavage product of APP. Moreover, all AD patients suffer from an accumulation of Aβ in brain, leading to the 'amyloid Aβ hypothesis' whereby AD is induced by Aβ amyloid accumulation in brain.

However, therapies that prevent or even reverse Aβ accumulation in brain have not been effective in treating AD. Furthermore, ApoE and TREM2 are not directly related to Aβ, but seem to influence microglial function, inflammatory responses, and/or lipid metabolism. Indeed, alterations in lipid content are a prominent feature of AD brains, suggesting that Aβ may be related to AD pathogenesis in a manner that is not related to amyloid formation.

Indeed, in preliminary experiments we observed that a chronic decrease γ-secretase activity, as would be observed with FAD-associated mutations of presenilin genes, causes a major decrease in synaptic transmission and an upregulation of cholesterol synthesis.

Based on all of these findings together, we here propose an interdisciplinary project that examines the role of changes in γ-secretase activity in synaptic function and lipid metabolism as a potential pathogenetic mechanism in AD. We describe four specific aims that will investigate the relationship of γ-secretase to synaptic transmission, the mechanism by which γ-secretase activity normally suppresses cholesterol synthesis, and the possibility that increased cholesterol synthesis induced by a chronic decrease in γ-secretase activity is responsible for the observed synaptic impairments.

Moreover, the proposed specific aims will explore the possibility that ApoE4, the ApoE variant predisposing to AD, also acts by altering lipid metabolism in neurons. These experiments will adopt a multidisciplinary approach that will be carried out in human neurons and in mouse brains, and will combine cell biology, transcriptomics, CRISPR, and electrophysiology techniques to explore the underlying mechanisms.

Among others, these experiments will contribute to our understanding of how presenilin mutations that cause FAD and impair γ-secretase activity affect synapses, and test the overall hypothesis that FAD-associated presenilin mutations and genetic ApoE variants predisposing to sporadic AD act by a common pathway regulating neuronal cholesterol levels, which in turn influences synaptic function.
Funding Goals
TO ENCOURAGE BIOMEDICAL, SOCIAL, AND BEHAVIORAL RESEARCH AND RESEARCH TRAINING DIRECTED TOWARD GREATER UNDERSTANDING OF THE AGING PROCESS AND THE DISEASES, SPECIAL PROBLEMS, AND NEEDS OF PEOPLE AS THEY AGE. THE NATIONAL INSTITUTE ON AGING HAS ESTABLISHED PROGRAMS TO PURSUE THESE GOALS. THE DIVISION OF AGING BIOLOGY EMPHASIZES UNDERSTANDING THE BASIC BIOLOGICAL PROCESSES OF AGING. THE DIVISION OF GERIATRICS AND CLINICAL GERONTOLOGY SUPPORTS RESEARCH TO IMPROVE THE ABILITIES OF HEALTH CARE PRACTITIONERS TO RESPOND TO THE DISEASES AND OTHER CLINICAL PROBLEMS OF OLDER PEOPLE. THE DIVISION OF BEHAVIORAL AND SOCIAL RESEARCH SUPPORTS RESEARCH THAT WILL LEAD TO GREATER UNDERSTANDING OF THE SOCIAL, CULTURAL, ECONOMIC AND PSYCHOLOGICAL FACTORS THAT AFFECT BOTH THE PROCESS OF GROWING OLD AND THE PLACE OF OLDER PEOPLE IN SOCIETY. THE DIVISION OF NEUROSCIENCE FOSTERS RESEARCH CONCERNED WITH THE AGE-RELATED CHANGES IN THE NERVOUS SYSTEM AS WELL AS THE RELATED SENSORY, PERCEPTUAL, AND COGNITIVE PROCESSES ASSOCIATED WITH AGING AND HAS A SPECIAL EMPHASIS ON ALZHEIMER'S DISEASE. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
Place of Performance
Stanford, California 94305 United States
Geographic Scope
Single Zip Code
Analysis Notes
Amendment Since initial award the total obligations have increased 414% from $733,803 to $3,770,432.
The Leland Stanford Junior University was awarded AD Pathogenesis: Role of γ-Secretase in Cholesterol Regulation Project Grant R01AG070919 worth $3,770,432 from National Institute on Aging in April 2021 with work to be completed primarily in Stanford California United States. The grant has a duration of 5 years and was awarded through assistance program 93.866 Aging Research. The Project Grant was awarded through grant opportunity Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional).

Status
(Ongoing)

Last Modified 6/20/25

Period of Performance
4/1/21
Start Date
3/31/26
End Date
88.0% Complete

Funding Split
$3.8M
Federal Obligation
$0.0
Non-Federal Obligation
$3.8M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to R01AG070919

Transaction History

Modifications to R01AG070919

Additional Detail

Award ID FAIN
R01AG070919
SAI Number
R01AG070919-3781972366
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NN00 NIH National Insitute on Aging
Funding Office
75NN00 NIH National Insitute on Aging
Awardee UEI
HJD6G4D6TJY5
Awardee CAGE
1KN27
Performance District
CA-16
Senators
Dianne Feinstein
Alejandro Padilla

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Institute on Aging, National Institutes of Health, Health and Human Services (075-0843) Health research and training Grants, subsidies, and contributions (41.0) $1,525,944 100%
Modified: 6/20/25